In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The Recursive Division Tree (RDT) algorithm is a mathematical process for measuring the logarithmic height of positive integers. For any integer ( n \ge 2 ), it recursively divides by logarithm-based ...

A large albino Burmese python, nicknamed "Nanners," was captured in Prosperity, South Carolina, after weeks on the loose. Local resident Warren Gallman and friends caught the snake, which had been ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Burmese pythons, while non-venomous, can inflict painful bites with sharp teeth, causing significant bleeding. The annual Florida Python Challenge offers over $25,000 in prizes to hunters removing ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...